Pharmacologic therapy for inflammatory bowel disease refractory to steroids

Area of Science:

• Gastroenterology and immunology
• Clinical pharmacology

Background:

• Corticosteroids are a cornerstone for inducing remission in inflammatory bowel disease (IBD).
• A significant proportion of IBD patients develop corticosteroid dependence or resistance, necessitating alternative therapeutic approaches.
• Effective management strategies for corticosteroid-refractory IBD are crucial for long-term patient outcomes.

Purpose of the Study:

• To review current literature on managing IBD refractory to corticosteroids.
• To propose evidence-based algorithms and optimization strategies for immunomodulator and biologic therapies in this patient population.

Main Methods:

• Comprehensive literature search focusing on randomized controlled trials, meta-analyses, and Cochrane reviews.
• Critical appraisal of existing evidence regarding treatments for corticosteroid-refractory IBD.
• Synthesis of findings to develop clinical management guidelines.

Main Results:

• Identified key immunomodulator and biologic agents effective in corticosteroid-refractory IBD.
• Outlined specific therapeutic algorithms based on disease characteristics and patient factors.
• Highlighted strategies for optimizing the use of advanced therapies to achieve and maintain remission.

Conclusions:

• Management of corticosteroid-refractory IBD requires a strategic approach beyond initial corticosteroid therapy.
• Immunomodulators and biologics offer viable and effective treatment options for patients unresponsive to corticosteroids.
• Proposed algorithms can guide clinicians in selecting and optimizing advanced therapies for improved IBD management.